PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Ana I.
Stancic has been named Senior Vice President and Chief Financial Officer
of the Company, effective June 8, 2011. Ms. Stancic has more than 20
years of extensive and diversified finance, accounting and operational
experience in the health care industry. In her new position, Ms. Stancic
will oversee Enzon's financial planning, strategy and controls as well
as its investor relations and information technology functions,
reporting to Ralph del Campo, Chief Operating Officer and Principal
Executive Officer of Enzon. Mark Ogden, who has served as Acting Vice
President, Finance and Principal Financial Officer while the Company
conducted a search for a Chief Financial Officer, will remain as a
consultant to Enzon on accounting and financial matters during a
transition period.
"Ana brings great depth of experience to Enzon and we are pleased to
have her as a member of the management team," stated Alex Denner,
Chairman of the Board. "We look forward to her contributions as Chief
Financial Officer, and thank Mark for his service to the Company."
Most recently, Ms. Stancic served as senior vice president and chief
financial officer of M2Gen, a wholly owned for-profit subsidiary of
Moffitt Cancer Center. Prior to that, she served as chief financial
officer of Aureon Biosciences, Inc., a private oncology diagnostic
company. From 2007 to 2008, she was executive vice president and chief
financial officer at Omrix Biopharmaceuticals, Inc., which was acquired
by Johnson & Johnson. From 2004 to 2007, Ms. Stancic was at ImClone
Systems, Inc., which was acquired by Eli Lilly, Inc. At ImClone, she
served in various financial roles, including senior vice president,
finance. Prior to joining ImClone, she was vice president and controller
at Savient Pharmaceuticals, Inc. She currently serves as a member of the
Board of Directors of Champions Oncology, Inc., KV Pharmaceutical and
Genta Incorporated.
Ms. Stancic began her career at PricewaterhouseCoopers in the Assurance
practice where she had responsibility for international and national
companies in the pharmaceutical and services industries. Ms. Stancic is
a Certified Public Accountant and holds an M.B.A. from Columbia
University Graduate School of Business.
About Enzon
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the
research and development of innovative therapeutics for cancer patients
with high unmet medical needs. Enzon's drug-development programs utilize
two platforms - Customized PEGylation Linker Technology (Customized
Linker Technology®) and third-generation mRNA-targeting
agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon
currently has four compounds in clinical development and multiple novel
LNA targets in preclinical research. Enzon receives royalty revenues
from licensing arrangements with other companies related to sales of
products developed using its Customized Linker Technology. Further
information about Enzon and this press release can be found on the
Company's website at www.enzon.com.
Forward Looking Statements
There are forward-looking statements contained herein, which can be
identified by the use of forward-looking terminology such as the words
"believes," "expects," "may," "will," "should," "potential,"
"anticipates," "plans," or "intends" and similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, events or
developments to be materially different from the future results, events
or developments indicated in such forward-looking statements. Such
factors include but are not limited to the timing, success and cost of
clinical studies for Enzon's product candidates, the ability to obtain
regulatory approval of Enzon's product candidates, Enzon's ability to
obtain the funding necessary to develop its product candidates, market
acceptance of and demand for Enzon's product candidates, and the impact
of competitive products, pricing and technology. A more detailed
discussion of these and other factors that could affect results is
contained in Enzon's filings with the U.S. Securities and Exchange
Commission, including Enzon's most recent Annual Report on Form 10-K for
the year ended December 31, 2010 . These factors should be considered
carefully and readers are cautioned not to place undue reliance on such
forward-looking statements. No assurance can be given that the future
results covered by the forward-looking statements will be achieved. All
information in this press release is as of the date of this press
release and Enzon does not intend to update this information.
Investor:
Argot Partners
Andrea Rabney, 212-600-1902
andrea@argotpartners.com
or
Media:
Argot
Partners
Meghan Feeks, 212-600-1902
meghan@argotpartners.com
Source: Enzon Pharmaceuticals, Inc.
News Provided by Acquire Media
